Bibliografia
 
  1. World Health Organization, HIV/AIDSFact sheet N°360, Updated October 2013. Disponibile all’indirizzo: www.who.int. Ultimo accesso in data 10 novembre 2013.
  2. Aggiornamento delle nuove diagnosi  di infezione da HIV e dei casi di AIDS in italia al 31 dicembre 2012, Notiziario ISS, Volume 26, n.9 suppl 1. Novembre 2013. Disponibile all’indirizzo www.iss.it. Ultimo accesso in data 12 novembre 2013.
  3. Lazzaretti C, Borghi V, Franceschini E, et al. Engagement and retention in care of patients diagnosed with HIV infection and enrolled in the Modena Hiv surveillance cohort. HIV 11, Glasgow 2012, P105.
  4. Vella S. Treatment 2.0 as a catalyst for Tasp  through Drug/Treatment Optimization In International Association of Physicians in AIDS Care (IAPAC). Evidence Summit “Controlling the HIV Epidemic With Antiretrovirals: Treatment as Prevention and Pre-Exposure Prophylaxis”, London 11-12 June 2012. Disponibile all’indirizzo www.iapac.org. Ultimo accesso in data 15 ottobre 2013.
  5. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379:2439- 48.
  6. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavirboosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012;379:2429-38.
  7. Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS. 2011;25(3):279–290.
  8. Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1 Luglio 2012. Disponibile all’indirizzo www.salute.gov.it. Ultimo accesso 30 novembre 2013.
  9. EACS European AIDS Clinical Society Guidelines-Version 7.0-October 2013. Disponibile all’indirizzo www.eacsociety.org. Ultimo accesso 19 ottobre 2013.
  10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. February 2013. Department of Health and
    Human Services. Disponibile all’indirizzo aidsinfo.nih.gov. Ultimo accesso 15 ottobre 2013.
  11. Olin JL, Spooner LM, Klibanov OM. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil
    Fumarate Single Tablet for HIV-1 Infection Treatment. Ann Pharmacother 2012;46:1671-7.
  12. Zolopa A, Sax PE, DeJesus E,  et al, GS-236-0102 Study Team A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results. J Acquir Immune Defic Syndr. 2013 May 1;63(1):96-100. 
  13. Rockstroh JK, DeJesus E, Henry K et al. GS-236-0103 Study Team. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):483-6. 
  14. Wohl D, Cohen C, Gallant J, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) has durable efficacy and differentiated long-term safety and tolerability versus efavirenz/emtricitabine/tenofovir DF (ATR) at week 144 in treatment-naive HIV patients. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013). Denver, September 10-13, 2013. Abstract H-672a.
  15. Cohen C, Wohl D, Gallant J et al. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) Has Durable Efficacy and Differentiated Safety Compared to EFV/FTC/TDF (ATR) Boosted by Ritonavir Plus Emtricitabine/Tenofovir DF in Treatment-naïve HIV-1 Infected Patients: Week 144 Results (102). EACS 2013, PE7/13. 
  16. Clumeck N, Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) Has Durable Efficacy and Differentiated Safety Compared to Atazanavir Boosted by Ritonavir Plus Emtricitabine/Tenofovir DF in Treatment-naïve HIV-1 Infected Patients: Week 144 Results (103). EACS 2013, LPBS7/2.
  17. Post F, Winston J, Hendry, B et al. Week 96 Renal Safety Update of EVG/COBI/FTC/TDF from Two Phase 3 Randomized Controlled Trials. 1st HIV Drug Therapy in the AmericasJune 13-15, 2013, Sau Paulo, Brazil, Poster #: P04.
  18. Stribild, SPMC. Disponibile all’indirizzo: http://www.ema.europa.eu
© Effetti srl